Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AbundRX vs MedLeanRx

AbundRX
Graded #192

Lower grade

vs+7.6000000000000085
MedLeanRx
Graded #69

Higher grade

The verdict

MedLeanRx takes it — 73.9/100 to 66.3/100.

MedLeanRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MedLeanRx is a physician-guided telehealth weight-loss clinic serving Texas only, based in Spring, TX.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedLeanRx +8
66
74
Dose & formulationMedLeanRx +29
64
93
Clinical oversightAbundRX +2
79
77
Labs & monitoringAbundRX +1
53
52
FulfillmentMedLeanRx +3
74
77
Contract termsEven
55
55
AbundRX · left barMedLeanRx · right bar

The numbers

MetricAbundRXMedLeanRx
WeighScore66.3/10073.9/100
GradeCC
Scorecard rank#192#69
Semaglutide$179/mo (compounded)$149/mo (starting dose, promotional rate, compounded)
Tirzepatide$279/mo (compounded)$269/mo (starting dose, compounded)
CoverageCoverage not published1 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
AbundRX

Graded #192 · C

Strengths

  • Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
  • Fast, free shipping and a simple few-minute online health assessment
  • Provider-guided care connecting patients with licensed US clinicians
  • Publishes Terms, Privacy, and Refund policies

Where it loses points

  • Claims LegitScript certification in text but displays no verifiable seal or listing
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Compounding pharmacy not named; no HIPAA notice found; state availability not published
  • Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
MedLeanRx

Graded #69 · C

Strengths

  • Compounded semaglutide $149/mo in both weekly injection and daily oral tablet form
  • Brand pathway for Wegovy, Zepbound, and Foundayo (orforglipron) at a $99/mo fee plus medication cost
  • Intro bundle: 2 months of compounded tirzepatide (2 mg weekly) for $325 — about $163/mo
  • LegitScript seal displayed; named supervising physician (Dr. Johnson Uzor, MD)
  • Free shipping, no hidden fees, and cancel-anytime plans per homepage trust chips

Where it loses points

  • Texas only — not available in the other 49 states
  • Compounded tirzepatide is $269/mo at standard pricing, above the ~$249 market median
  • Strict no-refund policy: 'All sales are final' per Terms & Conditions
  • Pharmacy partner not publicly named — a transparency gap for a compounding service
  • Legal entity name and founding details not published on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard